Dr Molly Millar is a Microbiologist in Genome Technologies within GPAS for the Pathogen Program at EIT. She is responsible for developing scalable, high-quality solutions for antimicrobial susceptibility testing (AST) of pathogens. The challenges facing the program are underpinned by the breadth of pathogen culture conditions and potential testing methods required to collect an unprecedented volume of AST data points and Molly is developing methods and strategy to implement this at EIT.

‍
Originally from Scotland, Molly holds a BSc (Honours) from Aberdeen University, completing various research projects in media optimisation for anaerobic bacteria at the Rowett Institute and in gene editing of Candida albicans with Aberdeen Fungal Group. Moving to England in 2018, Molly earned her doctorate at the University of East Anglia at the Quadram Institute Bioscience in Norwich. Her research was centred on investigating microbial phenotypes, in particular how bacterial genes and proteins involved in utilisation of dietary starch allow bacteria to produce beneficial metabolites. Molly worked at the institute's core sequencing service briefly before commencing postdoctoral research at the Wellcome Sanger Institute in Cambridge. Venturing into AST of pathogens, her work spanned microbe-microbe interactions in the human gut to developing methods to test intrinsic AMR of Vibrio (relevant to pandemic cholera). This led her to join EIT in March 2026.

‍
Outside of work, Molly currently enjoys taekwondo, as well as singing, cookery, baking, and menu design.

‍